INS and type 2 diabetes mellitus: Insulin secretagogues have shown a lower efficacy in reducing HbA1c with a higher risk of hypoglycemia in comparison with metformin; in addition, a higher mortality rate was observed in comparison with other glucose-lowering agents/placebo, and therefore, their use should be avoided for the treatment of type 2 diabetes.